Cargando…

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy

We report a case of recurrent small cell carcinoma of the uterine cervix that showed a complete response to paclitaxel, carboplatin, and bevacizumab (TC + Bev) combination therapy. Small cell carcinoma of the uterine cervix is extremely rare, with an incidence of only 1.3% in Japan, and a poor outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakao, Yuri, Tamauchi, Satoshi, Yoshikawa, Nobuhisa, Suzuki, Shiro, Kajiyama, Hiroaki, Kikkawa, Fumitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184850/
https://www.ncbi.nlm.nih.gov/pubmed/32355492
http://dx.doi.org/10.1159/000506446
_version_ 1783526661424152576
author Nakao, Yuri
Tamauchi, Satoshi
Yoshikawa, Nobuhisa
Suzuki, Shiro
Kajiyama, Hiroaki
Kikkawa, Fumitaka
author_facet Nakao, Yuri
Tamauchi, Satoshi
Yoshikawa, Nobuhisa
Suzuki, Shiro
Kajiyama, Hiroaki
Kikkawa, Fumitaka
author_sort Nakao, Yuri
collection PubMed
description We report a case of recurrent small cell carcinoma of the uterine cervix that showed a complete response to paclitaxel, carboplatin, and bevacizumab (TC + Bev) combination therapy. Small cell carcinoma of the uterine cervix is extremely rare, with an incidence of only 1.3% in Japan, and a poor outcome. The patient was a 62-year-old woman with a chief complaint of irregular vaginal bleeding. Magnetic resonance imaging showed a 10-cm irregular mass from the uterine corpus's posterior wall to the cervix. Abdominal total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node sampling were performed for suspected uterine sarcoma. Histopathological findings revealed small cell carcinoma with lymph node metastasis. Although 6 cycles of etoposide + cisplatin were performed, para-aortic lymph node recurrence was found 3 months after chemotherapy. Subsequently, the patient received 8 cycles of TC + Bev, which eliminated the metastases. The patient is currently alive at 24 months.
format Online
Article
Text
id pubmed-7184850
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-71848502020-04-30 Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy Nakao, Yuri Tamauchi, Satoshi Yoshikawa, Nobuhisa Suzuki, Shiro Kajiyama, Hiroaki Kikkawa, Fumitaka Case Rep Oncol Case Report We report a case of recurrent small cell carcinoma of the uterine cervix that showed a complete response to paclitaxel, carboplatin, and bevacizumab (TC + Bev) combination therapy. Small cell carcinoma of the uterine cervix is extremely rare, with an incidence of only 1.3% in Japan, and a poor outcome. The patient was a 62-year-old woman with a chief complaint of irregular vaginal bleeding. Magnetic resonance imaging showed a 10-cm irregular mass from the uterine corpus's posterior wall to the cervix. Abdominal total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node sampling were performed for suspected uterine sarcoma. Histopathological findings revealed small cell carcinoma with lymph node metastasis. Although 6 cycles of etoposide + cisplatin were performed, para-aortic lymph node recurrence was found 3 months after chemotherapy. Subsequently, the patient received 8 cycles of TC + Bev, which eliminated the metastases. The patient is currently alive at 24 months. S. Karger AG 2020-04-09 /pmc/articles/PMC7184850/ /pubmed/32355492 http://dx.doi.org/10.1159/000506446 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Nakao, Yuri
Tamauchi, Satoshi
Yoshikawa, Nobuhisa
Suzuki, Shiro
Kajiyama, Hiroaki
Kikkawa, Fumitaka
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
title Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
title_full Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
title_fullStr Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
title_full_unstemmed Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
title_short Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
title_sort complete response of recurrent small cell carcinoma of the uterine cervix to paclitaxel, carboplatin, and bevacizumab combination therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184850/
https://www.ncbi.nlm.nih.gov/pubmed/32355492
http://dx.doi.org/10.1159/000506446
work_keys_str_mv AT nakaoyuri completeresponseofrecurrentsmallcellcarcinomaoftheuterinecervixtopaclitaxelcarboplatinandbevacizumabcombinationtherapy
AT tamauchisatoshi completeresponseofrecurrentsmallcellcarcinomaoftheuterinecervixtopaclitaxelcarboplatinandbevacizumabcombinationtherapy
AT yoshikawanobuhisa completeresponseofrecurrentsmallcellcarcinomaoftheuterinecervixtopaclitaxelcarboplatinandbevacizumabcombinationtherapy
AT suzukishiro completeresponseofrecurrentsmallcellcarcinomaoftheuterinecervixtopaclitaxelcarboplatinandbevacizumabcombinationtherapy
AT kajiyamahiroaki completeresponseofrecurrentsmallcellcarcinomaoftheuterinecervixtopaclitaxelcarboplatinandbevacizumabcombinationtherapy
AT kikkawafumitaka completeresponseofrecurrentsmallcellcarcinomaoftheuterinecervixtopaclitaxelcarboplatinandbevacizumabcombinationtherapy